Pitney Dermatology, Toowong, Brisbane, Queensland, Australia.
Australas J Dermatol. 2020 Nov;61(4):318-323. doi: 10.1111/ajd.13321. Epub 2020 May 10.
The therapeutic value of ultraviolet A1 (UVA1) phototherapy has been acknowledged for many years. Initially developed predominately for experimental and diagnostic purposes, it was subsequently recognised as a beneficial therapeutic modality in atopic dermatitis and localised scleroderma, and more recently a variety of sclerosing and fibrosing dermatoses, T-lymphocyte mediated disorders, both inflammatory and infiltrative, and several predominately dermal processes previously unresponsive to current therapies.
We present a retrospective evaluation of outcomes and treatment tolerability in adult patients using a low dose (30 joules/cm ), regimen administered in our private dermatologic practice, between 2006 and December 2019.
Major clinical groups represented include atopic dermatitis, localised and systemic sclerodermas, mycosis fungoides, urticarial dermatitis, generalised pruritus and granuloma annulare. Eighty-seven patients are included in this study with 92% of all patients experiencing a beneficial result, 54% having complete and 38% partial relief of presenting signs and/or symptoms. UVA1 therapy was well tolerated, with no patients ceasing treatment due to adverse effects.
Ultraviolet A1 is an effective and safe treatment option in many hitherto recalcitrant cutaneous conditions.
多年来，紫外线 A1（UVA1）光疗的治疗价值已得到认可。最初主要开发用于实验和诊断目的，后来在特应性皮炎和局限性硬皮病中被认为是一种有益的治疗方式，最近在多种硬化和纤维化皮肤病、T 淋巴细胞介导的疾病中也得到了应用，包括炎症性和浸润性疾病，以及几种以前对现有治疗方法无反应的主要皮肤疾病。
我们回顾性评估了 2006 年至 2019 年 12 月期间在我们的私人皮肤科诊所中使用低剂量（30 焦耳/平方厘米）方案治疗的成年患者的结果和治疗耐受性。
主要临床代表包括特应性皮炎、局限性和系统性硬皮病、蕈样真菌病、荨麻疹性皮炎、全身性瘙痒和环状肉芽肿。本研究共纳入 87 例患者，其中 92%的患者均获得有益的治疗效果，54%的患者完全缓解，38%的患者部分缓解。UVA1 治疗耐受性良好，无患者因不良反应而停止治疗。
UVA1 是许多以前难治性皮肤疾病的有效且安全的治疗选择。
